{"result": "(\"entity\"<|>HORMONA ESTIMULANTE DE MELANOCITOS<|>EVENT<|>Hormona estimulante de melanocitos (α-MSH) is a hormone involved in the regulation of skin pigmentation and appetite.)\n##\n(\"entity\"<|>PROOPIOMELANOCORTINA<|>EVENT<|>Proopiomelanocortina (POMC) is a precursor polypeptide that is involved in the production of several hormones, including those that regulate appetite.)\n##\n(\"entity\"<|>HIPERTENSIÓN<|>EVENT<|>Hypertension is a medical condition characterized by consistently elevated blood pressure, which can be a contraindication for certain medications.)\n##\n(\"entity\"<|>CRISIS COMICIAL<|>EVENT<|>Crisis comicial refers to seizure episodes, which are contraindications for the use of bupropion-naltrexone in certain patients.)\n##\n(\"entity\"<|>INSUFICIENCIA RENAL<|>EVENT<|>Insuficiencia renal is a medical condition where the kidneys fail to filter waste from the blood effectively, affecting medication administration.)\n##\n(\"entity\"<|>DIABETES TIPO 2<|>EVENT<|>Diabetes tipo 2 is a chronic condition that affects the way the body processes blood sugar (glucose) and can be related to obesity.)\n##\n(\"relationship\"<|>BUPROPION-NALTREXONE<|>HIPERTENSIÓN<|>Bupropion-naltrexone is contraindicated in patients with uncontrolled hypertension<|>8)\n##\n(\"relationship\"<|>BUPROPION-NALTREXONE<|>CRISIS COMICIAL<|>Bupropion-naltrexone is contraindicated in patients with a history of seizure episodes<|>8)\n##\n(\"relationship\"<|>BUPROPION-NALTREXONE<|>INSUFICIENCIA RENAL<|>Bupropion-naltrexone is contraindicated in patients with renal insufficiency<|>8)\n##\n(\"relationship\"<|>OBESITY<|>DIABETES TIPO 2<|>Obesity is a significant risk factor for developing type 2 diabetes<|>9)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ona, al actuar como antagonista de los receptores µ-opioides, permite que la actividad del bupropión se mantenga durante largo tiempo.\n\nLas otras respuestas (A, B y D) son correctas.\n\nFigura 6. Mecanismo de acción de bupropión-naltrexona.\n\nα-MSH: hormona estimulante de melanocitos; POMC: proopiomelanocortina; R-MC4: receptor melanocortina-4.\nModificado de: Billes SK. Pharmacol Res. 2014;84:1-11.\n\nReferencias:\n- Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1-11.\n---\nOBESIDAD, LÍPIDOS Y TRASTORNOS ELECTROLÍTICOS 8\n\n## 9 En relación con la combinación bupropión-naltrexona, señale en qué situaciones estaría contraindicada su administración:\n\nA. En hipertensos.\nB. En pacientes con antecedentes de crisis comiciales.\nC. En pacientes con conductas alimentarias con atracones y picoteos.\nD. En pacientes con insuficiencia renal < 60 ml/min.\n\n### COMENTARIO\n\nLas contraindicaciones formales según ficha técnica de la combinación bupropión-naltrexona quedan establecidas en: hipertensión descontrolada, crisis maníaca o trastorno bipolar, glaucoma de ángulo estrecho, tratamiento con IMAO y antecedentes de crisis comiciales.\n\nLa toma de bupropión reduce el umbral convulsivo, especialmente si la medicación se ingiere con comidas grasas (aumenta sus concentraciones), por lo que en pacientes con epilepsia primaria o secundaria a un tumor o traumatismo del SNC estaría contraindicada.\n\nLa combinación bupropión-naltrexona, por el contrario, está indicada particularmente en pacientes con apetito, con especial predilección por el picoteo y/o los atracones, ya que actúa en los núcleos de recompensa (accumbens o amígdala), disminuyendo la frecuencia de estos episodios y contribuyendo a bajar de peso.\n\nReferencias:\n- Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22 Suppl 3:1-203.\n\n## 10 ¿Cuál de las siguientes técnicas de cirugía bariátrica tiene un mayor componente malabsortivo?\n\nA. Bypass gástrico proximal en Y de Roux.\nB. Cruce duodenal.\nC. Bypass gástrico en una anastomosis (OAGB: one-anastomosis gastric bypass).\nD. Gastrectomía vertical (Sleeve gastrectomy).\n\n### COMENTARIO\n\nEl cruce duodenal es una técnica malabsortiva que comprende dos pasos: el primero es la realización de una gastrectomía tubular, habitualmente más ancha que la gastrectomía vertical como técnica única. El segundo consiste en realizar una desconexión duodenal y una sección yeyunal, aproximadamente a 250 cm del ángulo de Treitz. El yeyuno más distal se anastomosa al duodeno (rama alimentaria), cruzando a otra asa (biliopancreática) que se anastomosa a 75-100 cm del íleon terminal (fig. 7).\n\n| Gastrectomía vertical | Bypass gástrico | Mini-bypass gástrico | Cruce duodenal |\n|:---------------------:|:----------------:|:--------------------:|:--------------:|\n| [Diagrama de gastrectomía vertical] | [Diagrama de bypass gástrico] | [Diagrama de mini-bypass gástrico] | [Diagrama de cruce duodenal] |\n\nFigura 7. Técnicas de cirugía bariátrica.\n\nEl bypass gástrico estándar y el realizado en una anastomosis (o mini-bypass gástrico) pueden también modificarse para crear una mayor malabsorción, dejando el asa biliopancreática más larga (y excluida del paso del alimento). Son modificaciones técnicas que se pueden emplear en sujetos superobesos con IMC > 45 kg/m².\n\nReferencias:\n- Rubio Herrera MA, et al. Manual de Obesidad mórbida. 2.ª ed. Madrid: Editorial Panamericana; 2015.\n---\nOBESIDAD, LÍPIDOS Y TRASTORNOS ELECTROLÍTICOS 8\n\n## 11. Un paciente con obesidad y diabetes tipo 2 insulinodependiente intervenido de gastrectomía vertical presenta al año tras la cirugía síntomas que aparecen inmediatamente tras la ingesta (entre 15 y 30 min) consistentes en malestar abdominal, sensación nauseosa, sudoración profusa, mareos y pal\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>BUPROPION-NALTREXONE<|>EVENT<|>Bupropion-naltrexone is a combination pharmacotherapy indicated for weight loss, particularly in patients with appetite issues and binge eating behaviors.)\n##\n(\"entity\"<|>BILL SK<|>PERSON<|>Bill SK is an author referenced in the pharmacological research regarding naltrexone/bupropion for obesity.)\n##\n(\"entity\"<|>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS<|>ORGANIZATION<|>The American Association of Clinical Endocrinologists provides clinical practice guidelines for the medical care of patients with obesity.)\n##\n(\"entity\"<|>GASTRECTOMY<|>EVENT<|>Gastrectomy is a surgical procedure that involves the removal of part or all of the stomach, often performed for obesity treatment.)\n##\n(\"entity\"<|>BYPASS GASTRIC<|>EVENT<|>Bypass gastric is a type of bariatric surgery that alters the digestive system to help with weight loss.)\n##\n(\"entity\"<|>CROSSING DUODENAL<|>EVENT<|>Crossing duodenal is a malabsorptive surgical technique that involves a two-step process to aid in weight loss.)\n##\n(\"entity\"<|>OBESITY<|>EVENT<|>Obesity is a medical condition characterized by excessive body fat, often leading to various health issues, including diabetes and hypertension.)\n##\n(\"relationship\"<|>BUPROPION-NALTREXONE<|>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS<|>The American Association of Clinical Endocrinologists provides guidelines that may include the use of bupropion-naltrexone for obesity treatment<|>7)\n##\n(\"relationship\"<|>BUPROPION-NALTREXONE<|>BILL SK<|>Bill SK authored research discussing the effectiveness of bupropion-naltrexone for obesity<|>8)\n##\n(\"relationship\"<|>GASTRECTOMY<|>BYPASS GASTRIC<|>Both gastrectomy and bypass gastric are surgical procedures aimed at treating obesity<|>6)\n##\n(\"relationship\"<|>CROSSING DUODENAL<|>GASTRECTOMY<|>Crossing duodenal is a technique that may involve gastrectomy as part of its procedure<|>5)\n##\n(\"relationship\"<|>OBESITY<|>BUPROPION-NALTREXONE<|>Bupropion-naltrexone is indicated for patients suffering from obesity<|>9)\n<|COMPLETE|>"}]}